Siemens Healthineers looking at several separation options

Siemens is moving ahead with the planned split of its healthcare division, Siemens Healthineers, with CFO Ralf Thomas listing three options for the $15 billion business: a spinoff, an initial public offering or a reverse merger with a public company.

The public listing plans were first announced in November 2016. On a conference call with reporters, Thomas said the company isn’t setting any deadline to make a decision.

“We're not in a hurry. We don't need to react very quickly,” he said, according to Reuters. “We don't believe that the market environment is going to completely flip overnight. That's why we don't feel under pressure.”

According to Bloomberg, an IPO for the unit could be worth $30 billion. The Healthineers business did fall short of market expectations in Siemens’ second fiscal quarter, though profits still rose 6 percent to $643 million.

In the meantime, the unit has continued to grow. In April, it announced its intention to acquire Medicalis, a provider of workflow technology and clinical decision support to radiology groups, imaging centers and hospitals, for an undisclosed amount. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.